Literature DB >> 6626579

Cell-free synthesis and transport of precursors of mutant ornithine carbamoyltransferases into mitochondria.

P Briand, S Miura, M Mori, L Cathelineau, P Kamoun, M Tatibana.   

Abstract

Synthesis, mitochondrial transport and processing of ornithine carbamoyltransferase (EC 2.1.3.3) were studied in mutant mice strains (sparse-fur, spf, and sparse-fur with abnormal skin and hair, spf-ash) which exhibit a deficiency in this enzyme. Spf mice have an increased amount (about 150% of control) of the enzyme with abnormal kinetic properties, whereas spf-ash mice have a decreased amount (about 10% of control) of the enzyme with apparently normal kinetic properties. Precursors of the mutant enzymes were synthesized in a reticulocyte lysate cell-free system. The hepatic level of translatable mRNA coding for the enzyme and the rate of the enzyme synthesis in liver slices of spf mice were 58 and 60% of the controls, respectively. In the case of spf-ash mice the activity of translatable mRNA for the enzyme was 10% of the controls. These results indicate that the decreased amount of ornithine carbamoyltransferase protein in spf-ash mice is due mainly to a decreased level of translatable mRNA for the enzyme, whereas the increase in the enzyme amount in spf mice is presumably the result of a decreased rate of enzyme degradation. The subunit molecular weight of the spf enzyme precursor was practically the same as that of the normal enzyme precursor (Mr 40 000). Both precursors synthesized in vitro could be taken up and processed similarly to an apparently mature form (Mr 37 000). In the case of spf-ash enzyme, two discrete in vitro products were observed on sodium dodecyl sulfate polyacrylamide gel; one comigrated with the normal enzyme precursor and the other moved slightly slower. Both products appeared to be taken up and processed to the mature form of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6626579     DOI: 10.1016/0304-4165(83)90379-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  Ornithine transcarbamylase deficiency: a case with a truncated enzyme precursor and a case with undetectable mRNA activity.

Authors:  H Kodama; A Ohtake; M Mori; I Okabe; M Tatibana; S Kamoshita
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

2.  Mosaic pattern of ornithine transcarbamylase expression in spfash mouse liver.

Authors:  N Shiojiri; H Imai; S Goto; T Ohta; K Ogawa; M Mori
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

3.  Molecular basis of ornithine transcarbamylase deficiency in spf and spf-ash mutant mice.

Authors:  A Ohtake; M Takayanagi; S Yamamoto; H Kakinuma; H Nakajima; M Tatibana; M Mori
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

4.  The spfash mouse: a missense mutation in the ornithine transcarbamylase gene also causes aberrant mRNA splicing.

Authors:  P E Hodges; L E Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

5.  Level of translatable messenger RNA coding for argininosuccinate synthetase in the liver of the patients with quantitative-type citrullinemia.

Authors:  M Sase; K Kobayashi; Y Imamura; T Saheki; K Nakano; S Miura; M Mori
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

6.  Correction of mouse ornithine transcarbamylase deficiency by gene transfer into the germ line.

Authors:  C Cavard; G Grimber; N Dubois; J F Chasse; M Bennoun; M Minet-Thuriaux; P Kamoun; P Briand
Journal:  Nucleic Acids Res       Date:  1988-03-25       Impact factor: 16.971

7.  Messenger RNA coding for argininosuccinate synthetase in citrullinemia.

Authors:  K Kobayashi; T Saheki; Y Imamura; T Noda; I Inoue; S Matuo; S Hagihara; H Nomiyama; Y Jinno; K Shimada
Journal:  Am J Hum Genet       Date:  1986-05       Impact factor: 11.025

8.  Functional characterization of the spf/ash splicing variation in OTC deficiency of mice and man.

Authors:  Ana Rivera-Barahona; Rocío Sánchez-Alcudia; Hiu Man Viecelli; Veronique Rüfenacht; Belén Pérez; Magdalena Ugarte; Johannes Häberle; Beat Thöny; Lourdes Ruiz Desviat
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

9.  Long-term effects of medical management on growth and weight in individuals with urea cycle disorders.

Authors:  Roland Posset; Sven F Garbade; Florian Gleich; Andrea L Gropman; Pascale de Lonlay; Georg F Hoffmann; Angeles Garcia-Cazorla; Sandesh C S Nagamani; Matthias R Baumgartner; Andreas Schulze; Dries Dobbelaere; Marc Yudkoff; Stefan Kölker; Matthias Zielonka
Journal:  Sci Rep       Date:  2020-07-20       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.